Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.38% | -3.56% | 0.76% | -3.12% | 7.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.38% | -3.56% | 0.76% | -3.12% | 7.12% |
| Cost of Revenue | 5.53% | -2.52% | -4.81% | -4.49% | -3.08% |
| Gross Profit | -2.72% | -4.01% | 3.20% | -2.47% | 11.78% |
| SG&A Expenses | -8.60% | -0.14% | -4.28% | -3.49% | -1.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.63% | -0.91% | -4.57% | -2.26% | 2.98% |
| Operating Income | 82.66% | -30.90% | 49.80% | -3.94% | 29.96% |
| Income Before Tax | 77.24% | -23.58% | -788.71% | -13.51% | -21.05% |
| Income Tax Expenses | -129.41% | 33.33% | 80.00% | -29,400.00% | 409.09% |
| Earnings from Continuing Operations | 81.41% | -23.98% | -800.54% | 99.62% | -36.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.41% | -23.98% | -800.54% | 99.62% | -36.22% |
| EBIT | 82.66% | -30.90% | 49.80% | -3.94% | 29.96% |
| EBITDA | 484.00% | -386.36% | 116.33% | -19.67% | 73.96% |
| EPS Basic | 81.84% | -21.06% | -782.00% | 99.62% | -28.73% |
| Normalized Basic EPS | 65.24% | -34.69% | 46.83% | -11.60% | 35.49% |
| EPS Diluted | 81.92% | -21.06% | -782.00% | 99.62% | -27.80% |
| Normalized Diluted EPS | 65.24% | -34.69% | 46.83% | -11.60% | 35.49% |
| Average Basic Shares Outstanding | 2.41% | 2.42% | 2.10% | 1.67% | 5.81% |
| Average Diluted Shares Outstanding | 2.41% | 2.42% | 2.10% | 1.67% | 5.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |